Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3522348 in healthy volunteers
NCT04559568Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2020
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LY3522348 (11 arms), sponsored by Eli Lilly and Company. Primary endpoint: Serious Adverse Events. Started Oct 2020; status: completed.
02
Drugs
LY3522348
Beyond the preview
Go deeper on NCT04559568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04559568.